首页> 外文期刊>Journal of liposome research >Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: in vitro characterization, ex vivo permeation and in vivo skin deposition study
【24h】

Investigating superiority of novel bilosomes over niosomes in the transdermal delivery of diacerein: in vitro characterization, ex vivo permeation and in vivo skin deposition study

机译:在透皮递送的二氧化尿器中调查新的嗜血素的优越性:体外表征,离体渗透和体内皮肤沉积研究

获取原文
获取原文并翻译 | 示例
           

摘要

Skin is considered the most accessible organ of the body because of its underlying capillary network. However, stratum corneum (SC), the upper most layer of skin, represents major diffusional barrier for most drugs. Hence, the use of edge activators (EAs) in designing novel elastic vesicles is hypothesized to impart their lipid bilayer with ultra-flexibility to trespass SC by high self-optimizing deformability. To confirm this hypothesis, this work aimed at developing novel bilosomes by modulating conventional niosomal composition using different bile salts as EAs and investigating their superiority over niosomes for transdermal delivery of diacerein (DCN), as model drug. Bilosomes were prepared by thin film hydration (TFH) technique according to full 31.22 factorial design to select the optimal formulation using Design-Expert? software. The optimal bilosomes (B6) showed nanosized vesicles (301.65?±?17.32?nm) and 100.00?±?0.00 % entrapment efficiency. Ex vivo permeation studies and in vivo evaluation revealed that B6 exhibited superior permeation and drug retention capacity compared to the conventional niosomal formulation and drug suspension. Furthermore, B6 was subjected to in vivo histopathological study using male Wistar rats which ensured its safety for topical application. Overall, the results confirmed the hypothesized superiority of bilosomes over niosomes for enhancing DCN flux across the skin.
机译:由于其潜在的毛细管网络,皮肤被认为是身体最可达的器官。然而,Stratum corneum(sc),上层皮肤层,对大多数药物来说是主要的扩散屏障。因此,假设在设计新的弹性囊泡时使用边缘激活剂(EA)以通过高自优化可变形性来赋予它们的脂质双层以侵入超灵活性以侵入SC。为了确认这一假设,这项工作旨在通过使用不同的胆汁盐调节常规的患者组合物作为EAS调节常规的术来组合物,并研究其对透皮递送的二氧化酶(DCN)作为模型药物的优越性。通过薄膜水合(TFH)技术根据完整的31.22因子设计来制备双偏模粒,以选择使用设计专家的最佳配方?软件。最佳的双染色剂(B6)显示纳米囊泡(301.65〜±17.32·nm)和100.00?±0.00%的夹紧效率。例如,与常规的憩室制剂和药物悬浮液相比,B6表现出B6表现出优异的渗透和药物保留能力。此外,使用雄性Wistar大鼠进行体内组织病理学研究进行B6,该研究确保其用于局部应用的安全性。总体而言,结果证实了脱圆锥体内的假设优势,以增强皮肤的DCN助焊剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号